Nasdaq: IKT

Inhibikase Therapeutics, Inc. (IKT)

Inhibikase Therapeutics, Inc. is a public company that reports to the U.S. Securities and Exchange Commission and trades on Nasdaq under the ticker IKT. Bright Analyst brings its financial statements, SEC filings, stock performance, news and peer comparisons together in one place, with AI analysis throughout.

Key facts

Ticker symbol
IKT
Exchange
Nasdaq
SEC CIK
1750149
Official filings
SEC EDGAR

Research IKT

  • Profile — Business description, headquarters, subsidiaries and corporate identifiers.
  • Financials — Income statement, balance sheet and cash flow from 10-K and 10-Q filings.
  • SEC Filings — Every 10-K, 10-Q and 8-K, readable inline with AI analysis.
  • Stock Analysis — Price chart, returns, technical indicators and related companies.
  • News — Latest headlines and press coverage.
  • Material Contracts — Material agreements filed as exhibits to SEC reports.
  • Benchmark — Stock performance against the S&P 500, Nasdaq-100 and Dow (through SPY, QQQ and DIA) and economic indicators.
  • Peer Comparison — Side-by-side financial ratios against industry peers.

Frequently asked questions

What is Inhibikase Therapeutics, Inc.'s stock ticker?

Inhibikase Therapeutics, Inc. trades under the ticker symbol IKT on Nasdaq. Its SEC Central Index Key (CIK) is 1750149.

Where can I read Inhibikase Therapeutics, Inc.'s SEC filings?

The IKT SEC Filings page lists the 10-K annual reports, 10-Q quarterly reports and 8-K current reports Inhibikase Therapeutics, Inc. has filed, with AI analysis. The original documents are also on SEC EDGAR.

How can I analyze IKT's financial statements?

The IKT Financials page shows Inhibikase Therapeutics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly, taken from its XBRL filings, with an AI analysis of each statement.

How does IKT compare with its peers and the market?

The IKT Peer Comparison page lines Inhibikase Therapeutics, Inc. up against industry peers on valuation, growth and profitability ratios, and the Benchmark page compares its stock with the S&P 500, the Nasdaq-100 and the Dow.

For information only — not investment advice.